

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-91 (canceled)

Claim 92 (Currently Amended): A method of immunizing an animal comprising the step of:

administering a Chlamydia psittaci antigen to an animal in an amount effective to induce an immune response against Chlamydia psittaci; wherein the Chlamydia psittaci antigen comprises the amino acid sequence as set forth as SEQ ID NO: 79.

Claim 93 (Cancelled)

Claim 94 (Currently Amended): The method of claim 92, wherein the method further comprises the step of:

administering a second Chlamydia psittaci antigen to an animal in an amount effective to induce an immune response against Chlamydia psittaci; wherein the second Chlamydia psittaci antigen comprises the amino acid sequence as set forth as SEQ ID NO: 97, ~~11~~, 13, ~~17~~, 23, or 27.

Claim 95 (Currently Amended): The method of claim 92~~93~~, wherein the method further comprises the step of:

administering a second Chlamydia psittaci antigen to an animal in an amount effective to induce an immune response against Chlamydia psittaci; wherein the second Chlamydia psittaci antigen comprises the amino acid sequence as set forth as SEQ ID NO: 11, ~~13~~, ~~17~~, 23 or 27.

Claims 96-103 (canceled)

Claim 104 (previously presented): The method of claim 92 wherein the step of preparing a *Chlamydia psittaci* antigen further comprises preparing the *Chlamydia psittaci* antigen in a pharmaceutically acceptable carrier.

Claim 105 (previously presented): The method of claim 94 wherein the steps of preparing a *Chlamydia psittaci* antigen and preparing a second *Chlamydia psittaci* antigen further comprises preparing the *Chlamydia psittaci* antigen and the second *Chlamydia psittaci* antigen in a pharmaceutically acceptable carrier.

Claim 106 (previously presented): The method of claim 95 wherein the steps of preparing a *Chlamydia psittaci* antigen and preparing a second *Chlamydia psittaci* antigen further comprises preparing the *Chlamydia psittaci* antigen and the second *Chlamydia psittaci* antigen in a pharmaceutically acceptable carrier.

Claim 107 (previously presented): The method of claim 92 wherein the animal is a bovine.

Claim 108 (previously presented): The method of claim 94 wherein the animal is a bovine.

Claim 109 (previously presented): The method of claim 95 wherein the animal is a bovine.

Claim 110 (previously presented): The method of claim 92 wherein the animal is a human.

Claim 111 (previously presented): The method of claim 94 wherein the animal is a human.

Claim 112 (previously presented): The method of claim 95 wherein the animal is a human.

Claim 113 (previously presented): The method of claim 92 wherein the animal is a mammal.

Claim 114 (previously presented): The method of claim 94 wherein the animal is a mammal.

Claim 115 (previously presented): The method of claim 95 wherein the animal is a mammal.

Claim 116 (previously presented): The method of claim 94 wherein the step of administering the second *Chlamydia psittaci* antigen comprises administering the second antigen simultaneously with the administration of the first antigen.

Claim 117 (previously presented): The method of claim 94 wherein the step of administering the second *Chlamydia psittaci* antigen comprises administering the second antigen subsequent to the administration of the first antigen.

Claim 118 (previously presented): The method of claim 94 wherein the step of administering the second *Chlamydia psittaci* antigen comprises administering the second antigen prior to administration of the first antigen.

Application No. 10/023,437
Reply to Advisory Action of September 19, 2007
Amendment Dated October 26, 2007

Claim 119 (previously presented): The method of claim 95 wherein the step of administering the second *Chlamydia psittaci* antigen comprises administering the second antigen simultaneously with the administration of the first antigen.

Claim 120 (previously presented): The method of claim 95 wherein the step of administering the second *Chlamydia psittaci* antigen comprises administering the second antigen subsequent to the administration of the first antigen.

Claim 121 (previously presented): The method of claim 95 wherein the step of administering the second *Chlamydia psittaci* antigen comprises administering the second antigen prior to administration of the first antigen.